Department of Pathology, St. John's Medical College, Bangalore, Karnataka, India.
Department of Pathology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Indian J Pathol Microbiol. 2024 Jul 1;67(3):564-568. doi: 10.4103/ijpm.ijpm_683_22. Epub 2023 Nov 9.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma accounting for about 40% of all lymphomas. The international prognostic index (IPI), which relies on clinical and laboratory parameters, is used as a prognostic tool in DLBCL. In this study, we have included cases of DLBCL not otherwise specified (NOS) type to test the usefulness of the biological subclassification of DLBCL by immunohistochemistry (IHC) using the Hans algorithm into the germinal center B-like (GCB) type and nongerminal center (non-GCB) type. We correlated the subtypes with the demographics, site of involvement, IPI scores, and stage.
A total of 152 cases of DLBCL reported from January 2010 to March 2018 were included in this study. Clinical data, treatment details, and follow-up were reviewed. Apart from the routine IHC markers for DLBCL, additional markers CD10, BCL6, and MUM 1 were performed to classify DLBCL into GCB type and non-GCB type using the Hans algorithm.
The median age of presentation was 53 years with male-to-female ratio of 2:1. Most of the patients presented with nodal involvement (56.6%); cervical lymph node is the most common site (46.5%). The majority of the patients presented in Ann Arbor stage 1 (44.8%). According to the international prognostic index, 34.8% had a score of 3 (high intermediate). After IHC studies, GCB subtype (51.5%) of DLBCL emerged as more common than non-GCB type (48.5%). The two subtypes differed significantly with regard to sex (i.e. GCB type was more common in males and non-GCB type in females) and showed no significance with regard to any of the other clinical features and prognostic parameters evaluated.
Our study showed that IHC was a useful tool to subclassify DLBCL into GCB and non-GCB subtypes and may be easily incorporated in routine clinical practice.
弥漫性大 B 细胞淋巴瘤(DLBCL)是最常见的 B 细胞淋巴瘤类型,约占所有淋巴瘤的 40%。国际预后指数(IPI)是一种基于临床和实验室参数的预后工具,用于 DLBCL。在这项研究中,我们纳入了非特指型弥漫性大 B 细胞淋巴瘤(NOS)病例,以测试使用 Hans 算法的免疫组织化学(IHC)对 DLBCL 的生物学分类是否有用,分为生发中心 B 样(GCB)型和非生发中心(non-GCB)型。我们将亚型与人口统计学、受累部位、IPI 评分和分期相关联。
纳入了 2010 年 1 月至 2018 年 3 月期间报告的 152 例 DLBCL 病例。回顾了临床数据、治疗细节和随访情况。除了常规的 DLBCL IHC 标志物外,还使用 CD10、BCL6 和 MUM 1 等额外标志物进行检测,根据 Hans 算法将 DLBCL 分为 GCB 型和 non-GCB 型。
中位发病年龄为 53 岁,男女比例为 2:1。大多数患者表现为淋巴结受累(56.6%);最常见的受累部位是颈部淋巴结(46.5%)。大多数患者处于 Ann Arbor 分期 1 期(44.8%)。根据国际预后指数,34.8%的患者评分为 3(中高危)。经免疫组化研究,生发中心 B 细胞样(GCB)型 DLBCL (51.5%)比非生发中心 B 细胞样(non-GCB)型(48.5%)更为常见。两种亚型在性别方面存在显著差异(即 GCB 型多见于男性,non-GCB 型多见于女性),而在其他任何临床特征和评估的预后参数方面均无显著差异。
我们的研究表明,免疫组化是一种将 DLBCL 分为 GCB 和 non-GCB 亚型的有用工具,并且可以很容易地纳入常规临床实践中。